Medical device manufacturer Medtronic, Inc. (MDT, Financial) reported results that were in-line with Wall Street analysts' expectations but demonstrated sequential improvement in underlying trends, including sales growth excluding foreign exchange affects. Medtronic's growth prospects benefited from market share gains in the Drug-eluting Stent (DES) business, with a better than expected launch of the Resolute Integrity stent. A focus on the international opportunities, specifically China, should also improve long-term potential.
From Diamond Hill Capital's third quarter Select Fund Commentary.
From Diamond Hill Capital's third quarter Select Fund Commentary.
